USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| - | Sep 30, 2021 | - | $-0.04 | - |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| - | Sep 30, 2021 | - | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 3 | $-0.75 | $-1.53 | $-0.36 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-0.75 | $-0.81 | $-0.83 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 3 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 17, 2021 | Jun 2021 | $-0.15 | $-0.04 | 73.33% |
| May 17, 2021 | Mar 2021 | $-0.16 | $-0.05 | 68.91% |
| Mar 9, 2021 | Dec 2020 | $-0.10 | $-0.16 | -60.00% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 9, 2021 | Dec 2020 | - | $-0.16 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 17, 2021 | Jun 2021 | $0.00 | $0.00 | - |
| May 17, 2021 | Mar 2021 | $0.00 | $0.00 | - |
| Mar 9, 2021 | Dec 2020 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 9, 2021 | Dec 2020 | - | $0.00 | - |
Gracell Biotechnologies's previous earnings date was Aug 17, 2021 for its fiscal quarter ended Jun 30, 2021.
GRCL's earnings per share (EPS) was $-0.04, beating the consensus analysts forecast of $-0.15 by 73.33%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -20.00%.
Revenues were $0.00.
The company reported a net income of $-96.22M.GRCL ended the quarter with $153.19M in total debt, an increase of 10.50% compared to the previous quarter.
Gracell Biotechnologies's previous annual earnings date was Mar 9, 2021 for its fiscal year ended Dec 31, 2020.
GRCL's earnings per share (EPS) was $-0.16.
Revenues were $0.00.
The company reported a net income of $-211.90M.
Gracell Biotechnologies reported a free cash flow of $-277.55M for its fiscal year, compared to $-191.82M a year ago.
The company ended the fiscal year with $102.89M in total debt, a decrease of -25.82% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
